Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: "Ed Stafford of Leicestershire, England walks in between trees as he walks through the Amazon jungle in Brazil in this undated handout photo. Former British army captain Stafford became on Monday the first known person to walk from the origin of the Amazon river, the world's second-longest river, to its mouth, after withstanding ""50,000"" mosquito bites, scorpion attacks and skin disease in his 859 day odyssey. REUTERS/Handout Ed Stafford, a 34-year-old from Leicestershire, England, dived into the Atlantic Ocean after taking 859 days to walk the length of the world’s second-longest river, starting at the peak of Mount Mismi in Peru in April 2008. “It’s just phenomenal to be here at the end of the journey after 2-1/2 years slogging our way through the jungle,” he told Reuters after arriving at the beach about 90 miles northeast of the Brazilian city of Belem. “It was really difficult to envisage how this was going to feel and I’m completely overwhelmed.”   Stafford briefly collapsed from exhaustion with only 52 miles of the 6,000-mile journey to go, passing out by the roadside after breaking out in a rash. “I feel slightly humbled that my system just decided to shut down so close to the finish,” he wrote on his blog at www.walkingtheamazon.com. Stafford has aimed to use the walk to raise awareness about the threats to the Amazon rain forest and its people, using a portable satellite video to blog about his trek. He had planned to complete the walk in about a year, but the journey was prolonged by floods that forced him to walk a roundabout route that was 2,000 miles longer than the 4,000-mile (6,400-km) length of the Amazon, which is exceeded in length only by Africa’s Nile river. He began the journey with fellow British adventurer Luke Collyer, but the pair had a falling out early in the trek and Stafford continued alone. He was joined in July 2008 by a Peruvian forestry worker, Gadiel Cho Sanchez Rivera, who pledged to walk with him for five days and has been with him on the walk ever since. A statement from Stafford’s media team said that the Briton had been: “wrongly accused of murder on two separate occasions, been imprisoned, had concrete stuffed in his mouth by hostile tribes people, been chased by Ashaninka Indians with bows and arrows, been stung by hundreds of wasps and watched as his guide ‘Cho’ removed a botfly from Ed’s head with superglue and a tree spine.”   It said he had endured “50,000” mosquito bites, lived on a diet of piranha fish, rice and beans, and dodged a variety of snakes, electric eels, scorpions, and ants, as well as contracting a skin-disfiguring disease. Famed British explorer Sir Ranulph Fiennes was quoted as saying in the statement that Stafford’s feat was “truly extraordinary.”   “No one has ever done this before and the pundits considered the route impossible,” he said." Claim: British man becomes first to walk Amazon length.
Example Output: A former British army captain became on Monday the first known person to walk from the origin of the Amazon river to its mouth, after enduring “50,000” mosquito bites, attacks by hostile Indians and tropical disease in his nearly 2-1/2 year odyssey.

Example Input: Paragraph: Cancer patients increasingly are having their care guided by gene tumor boards, a new version of the hospital panels that traditionally decided whether surgery, radiation or chemotherapy would be best. These experts study the patient’s cancer genes and match treatments to mutations that seem to drive the disease. “We dissect the patient’s tumor with what I call the molecular microscope,” said Dr. Razelle Kurzrock, who started a board at the University of California, San Diego, where Cairnes is treated. It’s the kind of care many experts say we should aim for — precision medicine, the right drug for the right person at the right time, guided by genes. There are success stories, but also some failures and many questions: Will gene-guided care improve survival? Does it save money or cost more? What kind of gene testing is best, and who should get it? “I think every patient needs it,” especially if cancer is advanced, said Kurzrock, who consults for some gene-medicine companies. “Most people don’t agree with me — yet. In five years, it may be malpractice not to do genomics.” Few people get precision medicine today, said Dr. Eric Topol, head of the Scripps Translational Science Institute. “The only thing that’s gone mainstream are the words.” HOW IT WORKS NOW If you have a cancer that might be susceptible to a gene-targeting drug, you may be tested for mutations in that gene, such as HER2 for breast cancer. Some breast or prostate cancer patients also might get a multi-gene test to gauge how aggressive treatment should be. Then most patients get usual guideline-based treatments. If there’s no clear choice, or if the disease has spread or comes back, doctors may suggest tumor profiling — comprehensive tests to see what mutations dominate. That’s traditionally been done from a tissue sample, but newer tests that detect tumor DNA in blood — liquid biopsies — are making profiling more common. The tests cost about $6,000 and many insurers consider them experimental and won’t pay. Gene tumor boards analyze what the results suggest about treatment. They focus on oddball cases like a breast cancer mutation in a colon cancer patient, or cancers that have widely spread and are genetically complex. The only options may be experimental drugs or “off-label” treatments — medicines approved for different situations. But as tumor profiling grows, it’s revealing how genetically diverse many tumors are, and that oddball cases are not so rare, said Dr. John Marshall. He heads the virtual tumor board at Georgetown Lombardi Comprehensive Cancer Center that also serves cancer centers in Pennsylvania, North Carolina, Michigan and Tennessee. “There is a little bit of faith” that testing will show the right treatment, but it’s not a sure thing, said Dr. Lee Schwartzberg, who heads one participating center, the West Cancer Center in Memphis. Dr. Len Lichtenfeld, the American Cancer Society’s deputy chief medical officer, is optimistic yet wary. Drugs that target BRAF mutations work well for skin cancers called melanomas, but less well for lung or colon cancers. “Just because a mutation occurs it doesn’t mean that drug is going to work in that cancer,” he said. LUCKY CASES When it does, results can be dramatic. Cairnes’ cancer was between her stomach and esophagus, and had spread to her liver, lungs and lymph nodes. Tissue testing found 10 abnormal genes, but on the liquid biopsy only EGFR popped out as a good target. Two drugs aim at that gene but aren’t approved for her type of cancer. A tumor board advised trying both — Erbitux and Tarceva, the drug her husband also had taken. Within two weeks, she quit using pain medicines. After two months, her liver tumor had shrunk roughly by half. There are signs that cancer may remain, but it is under control. She feels well enough to travel and to take care of her granddaughter. “I’m very, very grateful to have a targeted therapy,” Cairnes said. “I cannot expect a better outcome than what we’re seeing right now,” said her doctor, Shumei Kato. WHAT STUDIES SHOW But is gene-guided treatment better than usual care? French doctors did the first big test, with disappointing results. About 200 patients with advanced cancer were given whatever their doctors thought best or off-label drugs based on tumor profiling. Survival was similar — about two months. Another French study, reported in June, was slightly more encouraging on survival but exposed another problem: No drugs exist for many gene flaws. Tests found treatable mutations in half of the 2,000 participants and only 143 got what a tumor board suggested. Some doctors worry that tumor boards’ recommending off-label treatments diverts patients from research that would benefit all cancer patients. For example, the American Society of Clinical Oncology’s TAPUR study tests off-label drugs and shares results with their makers and federal regulators. LETTING PATIENTS CHOOSE Ann Meffert, who lives on a dairy farm in Waunakee, Wisconsin, endured multiple standard treatments that didn’t defeat her bile duct cancer. “She was going to be referred to hospice; there was not much we could do,” said Dr. Nataliya Uboha, who took the case to a tumor board at the University of Wisconsin-Madison. The panel gave several options, including off-label treatment, and Meffert chose a study that matches patients to gene-targeting therapies and started on an experimental one last October. “Two weeks in, I started feeling better,” she said, and when she saw test results, “I couldn’t believe the difference.” Many lung spots disappeared and the liver tumor shrank 75 percent. She is not cured, though, and doctors are thinking about next steps. And that could involve a fresh look at her tumor genes. ___ Marilynn Marchione can be followed at @MMarchioneAP __ This Associated Press series was produced in partnership with the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. Claim: Ultra-personal therapy: Gene tumor boards guide cancer care.
Example Output: Doctors were just guessing a decade ago when they gave Alison Cairnes’ husband a new drug they hoped would shrink his lung tumors. Now she takes it, but the choice was no guesswork. Sophisticated gene tests suggested it would fight her gastric cancer, and they were right.

Example Input: Paragraph: The Advocate reports national and local politicians, law enforcement, health care experts and social services professionals attended a summit Tuesday in Baton Rouge hosted by Republican U.S. Sen. Bill Cassidy of Louisiana. They agreed providing mental health services to keep patients out of emergency rooms and jail is vital, but the speakers said it must be a bottom-up effort. Cynthia Kemp says she had worked toward better service in Arlington, Virginia, roughly a decade ago, raising about $800,000 for a jail diversion program and crisis intervention team. She’s now with the federal Substance Abuse and Mental Health Services Administration. Cassidy says communities need to leverage local money to collect federal grant assistance. ___ Information from: The Advocate, http://theadvocate.com Claim: Mental health care summit: Local officials must lead effort.
Example Output:
Federal officials say Louisiana leaders must take the lead in addressing mental health care for their own communities.